Skip to content Skip to footer
Subscribe Now
Viewpoints_Maria Belvisi_Dr. Sarah Doffman_Dr. Janet Franklin
VIEWPOINTS

ATS 2024: Maria Belvisi, Sarah Doffman, and Janet Franklin from AstraZeneca & Amgen in a Stimulating Conversation with PharmaShots

Shots:  Jointly developed by AstraZeneca & Amgen, AZD8630/AMG targets Thymic stromal lymphopoietin (TSLP), an epithelial cytokine involved in Chronic Inflammatory Disorders  Recently, AstraZeneca and Amgen released the P-I data evaluating AZD8630/AMG104 on three doses vs. placebo for 28 days. The data demonstrated linear PK at all three doses  Today, at PharmaShots we have Prof. Maria…
October 7, 2024

Read more

Immunology Top 20 2024
TOP 20

Top 20 Immunology Companies of 2024

Shots: Immunology remains one of the most explored therapy areas. Companies focusing on immunology are steadfastly working to advance treatment options by developing drugs, vaccines, and antibodies In 2023, the global immunology market size was valued at $98.22B and expected to register $263.22B by 2033, with a CAGR of 10.36% from 2024 to 2033. AbbVie…
July 25, 2024

Read more

Amgen (2)
NEWS

Amgen’s Imdelltra (Tarlatamab-dlle) Receives the US FDA’s Approval to Treat Extensive-Stage Small Cell Lung Cancer 

Shots:  The US FDA has granted accelerated approval to Amgen’s Imdelltra (DLL3-targeting bispecific T-cell engager) for treating extensive-stage small cell lung cancer (ES-SCLC) adults whose disease progressed post Pt-based CT. Full approval depends upon confirmatory trials  The approval was based on the P-II (DeLLphi-301) study assessing Imdelltra (10mg, Q2W) in SCLC patients (n=99) failing on…
May 16, 2024

Read more

Insight+_Saurabh Chaubey
INSIGHTS+

Most Viewed Articles of 2023

2023, remained a busy year for PharmaShots. To keep our readers up to date on the developments in the healthcare sector, PharmaShots worked steadfastly to deliver real-time and real-world updates. Here’s a synopsis of our key reports and most-read news of the year.   Top 20 Radiopharma Companies Based on Market Cap  Shots:  Integrating scintigraphy with…
January 2, 2024

Read more

Companies Spending on R&D Top 20 2022
TOP 20

Top 20 Companies Spending on R&D in 2022

Shots: R&D (Research and Development) in the biopharma industry lays the foundation stone of innovative drugs. A robust R&D bolstered with new-age technological advances assures long-term sustainability in the future market With a global expenditure of $238B in 2022, the figures are anticipated to reach $285B by 2028. In 2022, AbbVie ranked the top among…
August 22, 2023

Read more

Insights+ Key Biosimilars Events of July 2023
INSIGHTS+

Insights+ Key Biosimilars Events of July 2023

Shots: Biosimilars are developed to be highly similar versions of approved biologics in terms of safety, purity, and potency Biosimilars are expected to be a cost-effective alternative to the high-priced branded biologics, offering significant and much-needed cost savings to both payers and the patients During the month of July, Samsung Bioepis reported P-III equivalence study…
August 4, 2023

Read more

Load more